Details

Autor(en) / Beteiligte

• Ahmed, Abrar
• Dingding, Chen

Titel

Clinical evaluation of carcinoembryonic antigen, carbohydrate antigen 125, carbohydrate antigen 199 and neuron-specific enolase in locally advanced-stage non-small cell lung cancer patients with adjuvant chemotherapy

Ist Teil von

• Current medicine research and practice, 2020-09, Vol.10 (5), p.215-221

Ort / Verlag

Wolters Kluwer India Pvt. Ltd

Erscheinungsjahr

2020

Link zum Volltext

Quelle

EZB-FREE-00999 freely available EZB journals

Beschreibungen/Notizen

• Background: Response markers carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 125, CA19-9 and neuron-specific enolase (NSE) constitute the common modulated parameters in non-small cell lung cancer (NSCLC). Objective: This study evaluated the pivotal role of biomarkers CEA, CA125, CA19-9 and NSE in the diagnosis and prognosis of NSCLC in both Stage IIIA and IIIB patients undergoing adjuvant chemotherapy. Materials and Methods: We adapted a retrospective design to review 1875 lung cancer patients' medical records from Jiangsu Province Cancer Hospital, Respiratory Department, from 2012 to 2017 who underwent surgery and were currently diagnosed with NSCLC. In total, 168 patients were eligible for final analysis. Blood samples from these patients were taken for CEA, CA125, CA19-9 and NSE analysis before and after each cycle of adjuvant chemotherapy. Results: A high level of CEA, CA125, CA19 9 and NSE was detected in 99 (58.92%), 87 (51.78%), 42 (25%) and 50 (29.76%) cases, respectively. Progression occurred in 56 of 168 patients, and their overall progression free survival (PFS) was 4-6 months. Patients with CEA level elevated and normal had a median PFS of 4 versus 8. Similarly, CA125, CA19 9 and NSE had a median PFS of 4 versus 6 (P = 0.001). In multivariable Cox regression model, treatment (2 vs. 3 drugs), metastasis (yes vs. no), CEA (≤3.5 ng/ml vs. >3.5 ng/ml) and CA125 (≤35 U/ml vs. >35 U/ml) (P = 0.01, P = 0.05, P < 0.0001 and P = 0.001, respectively) were found independent prognostic factors for PFS of NSCLC, and patients using three drug therapy showed prolonged PFS compared to those using two drug therapy (P = 0.001). Conclusions: Conclusively, we found that high pre-treatment levels CEA and CA125 correlated with poor prognosis and progression of the disease also occurred. In addition, in adjuvant chemotherapy, the use of bevacizumab with platinum-based chemotherapy showed a high efficacy in lowering tumour markers level and improved PFS.